Patents Assigned to Miravant Pharmaceuticals, Inc.
  • Patent number: 7521551
    Abstract: The present invention provides a process of preparation of naphthochlorins and other chlorins with annelated ring systems useful for photodynamic therapy and the compounds themselves. The method for producing naphthochlorin compounds include contacting compounds such as meso-(2?-hydroxymethyl)phenyl porphyrin or meso-(2?-N,N,N-trialkylaminomethyl)phenyl porphyrin precursors with at least one acid catalyst at sufficient temperature for a sufficient time to yield the desired conversion. In a similar manner chlorins possessing annelated ring systems may be made from compounds such as meso-(2?-hydroxymethyl)aryl porphyrins or meso-(2?-N,N,N-trialkylaminomethyl)phenyl porphyrin. The procedures described herein provide new routes for synthesizing naphthochlorins and chlorins with annelated ring systems.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: April 21, 2009
    Assignee: Miravant Pharmaceuticals, Inc.
    Inventors: Byron C. Robinson, Dipanjan Sengupta, Avinash Phadke
  • Patent number: 6906050
    Abstract: Substituted porphyrin and azaporphyrin deviations with various substitutents in the 12- and 17-positions of the porphyrin skeleton as pharmaceutical agents for use in photodynamic therapy, MRI diagnosis, and radiodiagnostics.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: June 14, 2005
    Assignee: Miravant Pharmaceuticals, Inc.
    Inventor: Byron C. Robinson
  • Patent number: 6827926
    Abstract: Metallotetrapyrrolic compounds having photherapeutic properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: December 7, 2004
    Assignee: Miravant Pharmaceuticals, Inc.
    Inventors: Byron C. Robinson, Ian M. Leitch, Stephanie Greene, Steve Rychnovsky
  • Patent number: 6794505
    Abstract: The present invention provides a process of preparation of naphthochlorins and other chlorins with annelated ring systems useful for photodynamic therapy and the compounds themselves. The method for producing naphthochlorin compounds include contacting compounds such as meso-(2′-hydroxymethyl)phenyl porphyrin or meso-(2′-N,N,N-trialkylaminomethyl)phenyl porphyrin precursors with at least one acid catalyst at sufficient temperature for a sufficient time to yield the desired conversion. In a similar manner chlorins possessing annelated ring systems may be made from compounds such as meso-(2′-hydroxymethyl)aryl porphyrins or meso-(2′-N,N,N-trialkylaminomethyl)phenyl porphyrin. The procedures described herein provide new routes for synthesizing naphthochlorins and chlorins with annelated ring systems.
    Type: Grant
    Filed: March 30, 2000
    Date of Patent: September 21, 2004
    Assignee: Miravant Pharmaceuticals, Inc.
    Inventors: Byron C. Robinson, Dipanjan Sengupta, Avinash Phadke
  • Patent number: 6605606
    Abstract: Solid forms of tin ethyl etiopurpurin (SnET2), including crystalline form I, crystalline Form II, disordered Form II, and an amorphous form are disclosed. Also disclosed are the 1,2-dichloroethane solvate of SnET2 and the N,N-dimethylformamide solvate of SnET2. These solid forms of SnET2 are useful as pharmaceuticals that exhibit pharmacological activity when irradiated with light and thus are useful in photodynamic therapy. Also disclosed are methods for making these solid forms of SnET2 and pharmaceuticals including these solid forms of SnET2.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: August 12, 2003
    Assignee: Miravant Pharmaceuticals, Inc.
    Inventors: G. Patrick Stahly, Barbara A. Garcia, Byron C. Robinson
  • Patent number: 6462192
    Abstract: Processes for the large scale production of tetrapyrrolic compounds useful as photosensitizers in photodynamic therapy, such as meso-formyl porphyrins, meso-acrylate porphyrins, purpurins and benzochlorins. In particular, tin ethyl etiopurpurin (SnET2) and the intermediates necessary for its production without chromatography are disclosed.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: October 8, 2002
    Assignee: Miravant Pharmaceuticals, Inc.
    Inventors: Byron C. Robinson, Barbara A. Garcia
  • Publication number: 20020137924
    Abstract: Processes for the large scale production of tetrapyrrolic compounds useful as photosensitizers in photodynamic therapy, such as meso-formyl porphyrins, meso-acrylate porphyrins, purpurins and benzochlorins. In particular, tin ethyl etiopurpurin (SnET2) and the intermediates necessary for its production without chromatography are disclosed.
    Type: Application
    Filed: January 23, 2001
    Publication date: September 26, 2002
    Applicant: Miravant Pharmaceuticals, Inc.
    Inventors: Byron C. Robinson, Barbara A. Garcia
  • Patent number: 6444194
    Abstract: The invention disclosed herein involves a phototherapeutic pyrrolic core complexed with a non-radioactive Indium atom. Complexation of Indium by the pyrrolic core forms a metalopyrrolic compound which influences enables these compounds to localize at target sites a phototherapy. Such functionally aids in both detection and phototherapy of disease sites, or provides functionality that binds to site specific receptors of a target area such that the therapy is improved.
    Type: Grant
    Filed: May 26, 1999
    Date of Patent: September 3, 2002
    Assignee: Miravant Pharmaceuticals, Inc.
    Inventors: Byron C. Robinson, Avinash S. Phadke
  • Patent number: 6376483
    Abstract: Bacteriochlorins and bacteriopurpurins useful for photodynamic therapy and methods for their manufacture are described herein. Methods for producing the claimed compounds include contacting meso-diacrylate porphyrin precursors with a solvent and a base catalyst at sufficient temperature and time to yield the desired conversion. Reduced bacteriochlorins can be produced by contacting unsaturated bacteriochlorins or bacteriopurpurins with a hydrogenation catalyst and hydrogen. These methods provide new routes for synthesizing bacteriochlorins and bacteriopurpurins from symmetrical and asymmetrical meso-diacrylate porphyrins.
    Type: Grant
    Filed: May 27, 1999
    Date of Patent: April 23, 2002
    Assignee: Miravant Pharmaceuticals, Inc.
    Inventor: Byron C. Robinson
  • Patent number: 6054449
    Abstract: A broad class of photosensitive compounds having enhanced in vivo target tissue selectivity and versatility in photodynamic therapy. Many furocoumarin compounds, such as psoralens, exhibit cytostatic activity when photoactivated but exhibit little in vivo specificity for selectively accumulating in any particular target tissue such as atheromatous plaques. Reactive Oxygen Producing Photosensitizers ("ROPPs") are photoactivatable compounds having an affinity for hyperproliferating cells (such as atheromatous plaque cells), which when photoactivated, produce cytotoxic reaction products. The photoactivity of a ROPP, such as a porphyrin, may be reduced by metalating the porphyrin while the selective affinity of the metalized ROPP for hyperproliferating tissue remains substantially unchanged.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: April 25, 2000
    Assignee: Miravant Pharmaceuticals, Inc.
    Inventors: Byron Robinson, Alan R. Morgan, Hugh L. Narciso, Jr.
  • Patent number: 5973141
    Abstract: An improved method for the demethoxycarbonylation of porphyrinic compounds such as pheophorbides involving reacting the starting porphyrinic compound with a high boiling point solvent to which a selected amount of water has been added.
    Type: Grant
    Filed: November 27, 1998
    Date of Patent: October 26, 1999
    Assignee: Miravant Pharmaceuticals, Inc.
    Inventors: Byron C. Robinson, Avinash S. Phadke, Shwn-Ji Susie Hwang Lee, Dipanjan Sengupta